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Abstract: 
Nucleoside analogues are active therapeutic agents for different types of diseases e.g. 
Cancer and virus infections. However, they are associated with several side effects due 
to off-target accumulation. Particulate delivery systems such as nanoparticles (NP) may 
be able to selectively target drug into affected organs and lower or omit off-target 
accumulation. Hydrophilic nucleoside analogues are poorly incorporated into NP. This 
work has used boronic compounds to synthesize more hydrophobic biodegradable pro-
drugs of hydrophilic nucleosides to improve drug loading into NP. Ribavirin (RV) was 
used as a model hydrophilic nucleoside to test our hypothesis.  RV is a broad antiviral 
agent, active against both RNA and DNA viruses. RV accumulates into Red Blood Cells 
(RBCs) causing haemolytic anaemia that restricts its therapeutic benefits. RBCs are 
reported to have no endocytic mechanisms. So, NP delivery should be advantageous. 
Two hydrophobic pro-drugs of RV were synthesized namely, ribavirin conjugated to 
phenylboronic acid and ribavirin conjugated to 4-butoxy-3, 5-dimethylphenylboronic 
acid and were encapsulated into polymer NP. It was shown that the pro-drugs were 
incorporated more effectively into polymer nanoparticles with a 1700 fold improved 
RV loading. Polymer NP had been prepared with biocompatible and biodegradable 
polymers, Poly(glycerol adipate) and its more hydrophobic derivatives. 
Keywords: Polymer nanoparticles; Poly (glycerol adipate); acylated Poly (glycerol 
adipate); phenyl boronic acid compounds; hydrophilic nucleoside 
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1. Introduction: 
Nucleoside analogues have been broadly used clinically as anticancer and antiviral 
agents. Being an antiviral, they have an important role for eradication of life threatening 
chronic virus infections such as AIDS (1); (2), Hepatitis B (3); (4) and Hepatitis C 
viruses (HCV) (5); (6) as well as acute virus infection e.g. Influenza virus that could be 
life threatening for children, pregnant women and elderly people at time of local 
outbreaks e.g. Spanish Influenza (7). However, nucleosides analogue administration is 
associated with several side effects that limit its clinical benefit. Zidovudine can induce 
cardiac and skeletal muscle myopathy (8); (9). Peripheral neuropathy is commonly seen 
with didanosine and stavudine, lactic acidosis is observed after didanosine, and 
stavudine administration and can have a fatal outcome due to extreme mitochondrial 
toxicity (9). Fialuridine, is another nucleoside analogue used for treatment of hepatitis 
B and it also causes mitochondrial poisoning that has resulted in the death of five 
patients (10); (11). Application of the following anticancer agents, Fludarabine, 
Cytarabine, Gemcitabine, Fluorouracil, Capecitabine is mainly associated with 
myelosuppression as a main side effect (12). A further drawback of nucleoside analogue 
administration is development of resistance (13) and cross-resistance to other 
compounds due to up-regulation of the P-glycoprotein drug efflux pump responsible for 
excretion of toxic compounds and a variety of different drugs (14). Therefore, finding 
a selective delivery system that could deliver these nucleoside analogues to the target 
tissue while decreasing or avoid their accumulation in off target tissues and nucleoside 
resistance due to P-glycoprotein will result in a dramatic improvement of their 
therapeutic efficacy and safety. 
Nanoparticles (NP) are an advanced delivery system and interest in their clinical 
development for different diseases has been growing over the last couple of decades. 
Advantages of NP include the ability to control the particle size, modify the particle 
surface properties and by attaching specific ligands, it could target certain organs or 
cells. NP have also the ability to sustain drug release. Together, these properties pave 
the way for more efficient and safe delivery of therapeutic agents. NP involve different 
particulate systems such as liposomes and polymer nanoparticles, etc. Nanoparticles 
may be particularly appropriate for liver delivery as the liver filters out nanoparticles 
very efficiently so there is a prospect for a high localisation of nanoparticles. Whereas 
for most applications PEGylated polymers are used to enhance circulation of 
nanoparticles, delivery to the liver may be facilitated by particles which have a low or 
no PEG surface covering. 
Ribavirin (RV) was selected to be used as a model of hydrophilic nucleosides in the 
current study due to its broad antiviral spectrum against RNA and DNA viruses (15). 
RV was previously a drug of choice to be used in combination with PEGylated 
interferon for treatment of  HCV (16); (17) and it is still used in some regimen of HCV 
for patients suffered from Cirrhosis (18); (19) and infected with genotype 1a (20) and 
genotype 3 (21); (22) and genotype 4 (23) and it has an added value by shorten the 
duration of treatment for patients with Genotype 1 and compensated Cirrhosis (24). RV 
in combination with asunaprevir, daclatasvir, vaniprevir plus pegylated interferon alfa 
2b have been approved for treatment of Genotype 1 in Japan (25). Furthermore, it is still 
the recommended drug for HCV treatment in some poor countries due to the high cost 
of Direct Acting Antivirals (DAA) (26). Although DAA dangerously threaten RV future 
in HCV treatment, RV is still an antiviral agent that could be used in treatment of 
chikungunya virus (27); (28), norovirus (29); (30); (31); (32) and it had been used in 
treatment of outbreaks of dengue virus (33),  Hendra and Nipah viruses (34),  Marburg 
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virus (35) and lassa virus (36). Due to the continuous emergence of new viruses and the 
long time required to develop new and effective antiviral agents. Scientists thought it is 
beneficial to make use of the currently FDA approved antivirals, especially it is known 
that viruses from the same family share similar features (37) and therefore might be 
treated with one of the licensed antiviral agents. Many of the emerging viruses belong 
to virus’s families that are currently being treated with one or more of the licensed 
antiviral drug (33). Many of licensed antiviral drugs could be used for treatment of 
viruses belong to different families (38).Therefore, development of a delivery system 
of the current licensed antiviral agents to improve their efficacy and decrease side 
effects should have a positive impact on future of antiviral therapy. RV as many other 
nucleosides analogues, its administration is accompanied by side effect, haemolytic 
anaemia, due to RV accumulation into Red Blood Cells (RBCs) (39). RBCs are reported 
to have no endocytic mechanisms (40). Polymer nanoparticles have been extensively 
investigated for encapsulation of drugs, as they are relatively cheap to produce and a 
number of different methodologies are available to optimise encapsulation (41); (42); 
(43). A high level of encapsulation is important to ensure that sufficient drug can be 
delivered to the target to achieve a useful therapeutic effect.  However, a number of 
publications have reported that hydrophilic molecules e.g. Gemcitabine, Zalacitabin are 
incorporated to a lower extent than hydrophobic molecules (44); (45).  A different 
strategy is therefore required for encapsulation of these drugs into polymer 
nanoparticles.  
In general, we would expect that a relatively hydrophilic drug would favour partitioning 
of the drug into the outside aqueous medium, rather than in the hydrophobic core of the 
NP. Also, it would favour diffusion of the drug from the NP into the surrounding 
aqueous medium after loading leading to a rapid drug release. In this paper, we 
hypothesized that synthesis of a more hydrophobic prodrug of hydrophilic nucleoside 
analogues using boronic acid derivatives might improve nucleoside loading into 
polymer nanoparticle and hence, its clinical application. However, this hydrophobic 
pro-drug should be able to degrade under physiological conditions to release the drug 
(hydrophilic nucleoside) in a therapeutically active form. RV is a purine analogue and 
so development of a strategy for this drug may also be of relevance for other nucleoside 
analogues. 
We have selected the use of boronic acid derivatives for this strategy due to their distinct 
properties of selective binding to 1,2 Cis diols which are present in the sugar ring of the 
nucleoside analogue (46). This should generate a more hydrophobic compound through 
formation of a reversible boronic ester covalent linkage that can be easily degraded 
under physiological conditions to yield the active nucleoside analogue. It is worth 
noting that the end product of boronic ester degradation is boric acid which is reported 
to have no toxicity to humans (47). In our group we have also developed the poly 
(glycerol adipate) (PGA) family of polymers. PGA is enzymically synthesised and has 
a pendant hydroxyl group on every co-monomer unit that can be easily modified with 
acyl groups to change the hydrophobicity of the polymer which can result in increased 
drug loading (48).In this paper we have therefore explored the possibility of producing 
more hydrophobic prodrugs in conjunction with a polymer whose physicochemical 
properties can be tailored to the drug to enhance the drug loading of nanoparticle 
formulations. 
2. Materials and Methods: 
2.1. Materials: 
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All materials were purchased from Sigma-Aldrich and VWR except divinyladipate 
purchased from Tokyo Chemical Industry UK Ltd. Phenylboronic Acid Solid Phase 
Extraction cartridges were purchased from Agilent company. Purified water ELGA, 
Model ELEC 25 (ELGA 13 KΩ resistivity) while HPLC water (ELGA 18 KΩ
resistivity) was used for HPLC work. Ribavirin was granted as a gift by October Pharma 
Company, Cairo, Egypt. 
 
2.2. Methods: 
2.2.1. Synthesis and characterization of PGA and its acylated derivatives:  
PGA and its acylated polymers, 20%-C18 PGA, 20%-C8PGA and 40%-C8PGA were synthesized 
as previously reported (48), (Figure 1). Briefly, PGA was synthesized by dissolving Equal 
amounts (250 mmol) of glycerol and DVA in dry tetrahydrofuran (THF, 30 ml) in presence of 
a catalytic enzyme, Novozyme 435 (1.25 gm) and the reaction was stirred (overhead stirrer, 200 
rpm) at constant temp (50 ̊ C) for 24h. This followed by enzyme filtration and evaporation of 
THF to obtain a yellowish Jelly-like polymer, its Mn, SEC = 11.6 kDa and molecular weight 
dispersity Ð of 1.4 and the molecular weight (Mw) was around 16 KDa as revealed by SEC 
characterization. 
 
For Acylated polymers synthesis, Figure 1, the previously synthesized PGA (2.10 g, 10.4 mmol) 
was dissolved and refluxed (2h) in dry THF (10 ml) in the presence of acyl chloride, either 2.05 
mmol or 4.1 mmol and pyridine (2ml) to obtain 20% or 40% acylation percentage respectively. 
HCl (2M, 100 ml) and Dichloromethane (50 X 3) were used to extract the acylated polymers. 
Then, organic phase was washed with water (100ml) and dried over magnesium sulfate. The 
polymer was collected after evaporation of solvent by rotary evaporator. Acylation percentage 
(20% and 40%) refers to the percentage of hydroxyl groups modified along the polymer 
backbone.  
 
Gel Permeation Chromatography (GPC) was performed for determination of polymer molecular 
weight and molecular weight dispersity Ð. Accordingly,  polymer samples (20 mg) were 
dissolved in THF (2 ml) then the solutions were mixed for an hour on the roller-mixer (SRT1, 
Stuart) to allow the polymers to fully dissolve followed by sample filtration using a syringe 
membrane nylon filter (0.2 μm) followed by SEC analysis as previously reported (48).  
 
2.2.2. Synthesis and characterization of RV-PBA and RV-BPBA: 
Phenyl boronic acid (PBA) and 4-butoxy-3,5-dimethyl phenyl boronic acid (BPBA) 
were conjugated to ribavirin (RV) using the previous reported methodology (49). 
Briefly, a pyridine solution of PBA or BPBA (5 mmol in 50 ml of solvent) was added 
dropwise to equimolar amount of RV dissolved in pyridine (5 mmol, 100 ml) in a 250 
ml-RBF. The solution was refluxed for 2 h, then pyridine was evaporated under vacuum. 
Dry acetone (5 ml) was added into the product and the resulting mixture was then added 
dropwise into dry diethyl ether (150 ml), the resulting precipitate was filtered off and 
dried in vacuum desiccator overnight.  
 
2.2.3. 1H-NMR Spectroscopy: 
The NMR spectra were recorded on Bruker AVIII HD 400 MHz NMR using a BBFO+ probe 
and are expressed in parts per million (δ) from internal tetramethylsilane. Polymer samples were 
dissolved in acetone-d6. RV-PBA and RV-BPBA, RV, PBA and BPBA were dissolved 
in.acetone-d6, chloroform-d, DMSO-d6, acetone- d6 and chloroform-d respectively. 
PGA: 1H NMR (400 MHz, Acetone-d6) δ 5.34 – 5.22 (m, 0H), 5.12 – 5.03 (m, 0H), 4.46 – 
3.99 (m, 5H), 3.74 – 3.49 (residual THF), 2.43 – 2.26 (m, 4H), 2.05 (acetone-d6), 1.85 – 1.72 
(residual THF),1.70 – 1.58 (m, 4H). 20%C8PGA: 1H NMR (400 MHz, Acetone-d6) δ 5.37 – 
5.20 (m, 1H), 5.16 – 5.02 (m, 1H), 4.45 – 3.98 (m, 5H), 2.47 – 2.23 (m, 6H), 2.05 (acetone-d6), 
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1.74 – 1.52 (m, 6H), 1.38 – 1.21 (m, 8H), 0.97 – 0.79 (m, 3H). 40%C8PGA: 1H NMR (400 
MHz, Acetone-d6) δ 5.38 – 5.20 (m, 1H), 5.12 – 5.02 (m, 1H), 4.42 – 3.94 (m, 5H), 3.74 – 3.49 
(residual THF), 2.44 – 2.23 (m, 6H), 2.05 (acetone-d6), 1.85 – 1.72 (residual THF), 1.71 – 1.50 
(m, 6H), 1.39 – 1.18 (m, 8H), 0.95 – 0.83 (m, 3H). 20%C18PGA: 1H NMR (400 MHz, 
Acetone-d6) δ 5.36 – 5.22 (m, 1H), 5.13 – 5.02 (m, 1H), 4.49 – 3.98 (m, 5H), 2.47 – 2.19 (m, 
6H), 2.05 (acetone-d6),1.74 – 1.50 (m, 6H), 1.39 – 1.21 (m, 28H), 0.95 – 0.81 (m, 3H). RV: 1H 
NMR (400 MHz, DMSO-d6) δ 8.87 (s, 1H), 7.86 – 7.79 (m, 1H), 7.61 (s, 1H), 5.81 (d, J = 3.9 
Hz, 1H), 5.57 (d, J = 5.6 Hz, 1H), 5.19 (d, J = 5.6 Hz, 1H), 4.91 (t, J = 5.6 Hz, 1H), 4.35 (td, J 
= 5.2, 4.0 Hz, 1H), 4.13 (q, J = 5.2 Hz, 1H), 3.94 (q, J = 4.8 Hz, 1H), 3.63 (dt, J = 11.9, 5.5, 4.1 
Hz, 1H), 3.49 (dt, J = 12.0, 5.3 Hz, 1H). RV-PBA: 1H NMR (400 MHz, Acetone-d6) δ 8.76 
(s, 1H), 7.82 (dd, 2H), 7.55 (dt, 1H), 7.44 (dt, 3H), 6.40 (d, J = 1.7 Hz, 1H), 5.69 (dd, J = 6.8, 
1.7, 0.5 Hz, 1H), 5.39 (dd, J = 6.9, 2.2, 0.6 Hz, 1H), 4.52 (td, 1H), 4.31 (t, J = 5.8 Hz, 1H), 3.83 
– 3.73 (m, 1H), 3.71 – 3.63 (m, 1H), 2.05 (acetone-d6). RV-BPBA: 1H NMR (400 MHz, 
Chloroform-d) δ 8.36 (s, 1H), 7.50 (s, 2H), 7.26 (chloroform-d),  6.12 (d, J = 2.0 Hz, 1H), 5.52 
(dd, J = 6.9, 2.1 Hz, 1H), 5.34 (dd, J = 6.8, 2.2 Hz, 1H), 3.93 (d, J = 12.6 Hz, 1H), 3.79 (t, J = 
6.5 Hz, 3H), 3.22 (s, 2H), 2.5 (DMSO-d6),  2.30 (s, 6H), 1.88 – 1.72 (m, 2H), 1.54 – 1.47 (m, 
1H), 1.00 (t, J = 7.4 Hz, 3H). 
 
2.2.4. Preparation of ribavirin nanoparticles: 
 
2.2.4.1. PGA NP:  
The nanoparticle dispersions were prepared by the nano-precipitation method (48). 
Briefly, PGA (20 mg) was dissolved in acetone (2 ml) to form the organic phase that 
was added dropwise while stirring into the aqueous phase, ammonium phosphate buffer 
(1 mM, 5 ml, pH 6.3) containing RV (20 mg). RV-PBA/RV-BPBA PGA NP were 
prepared in a similar way except that the polymer and RV-PBA or RV-BPBA (10 mg) 
were dissolved together in acetone or THF respectively (2 ml) and the aqueous phase 
was HEPES buffer (5 ml, 10 mM, pH 8). The nanoparticle dispersion was left to stir 
overnight for complete evaporation of organic solvent and formation of NP. 
 
2.2.4.2. Acylated PGA NP: 
Acylated polymers were used to prepare NP of the pro-drugs using a nano-precipitation 
method. The nano-precipitation was carried out as previously described except the 
organic phase (3ml) and calcium hydroxide (0.3 mM, 5 ml or 10 ml) as an aqueous 
phase were used instead. A set of 20%-C18PGA NP were also prepared in the presence 
of Tween 80 (0.05%, relative to the aqueous phase).  
 
2.2.5. Purification of polymer nanoparticles: 
All NP were purified to remove un-encapsulated free drug by gel filtration 
chromatography. The NP sample was loaded onto a sepharose CL-4B column (C2.5 X 
40, Pharmacia, bed volume 91ml). The column was eluted using a peristaltic pump at a 
flow rate of (1 ml/min) and collected in fractions (1.5ml/ tube). Calcium hydroxide (0.5 
µM) was used as the eluent for all types of drug loaded NP except RV PGA NP where 
ammonium phosphate buffer (1 nM, pH 6) was used as an eluent. The peaks of drug 
containing NP and free drug were detected using a Pharmacia chromatographic UV 
detector (206nm filter).  
 
2.2.6. Characterisation of nanoparticles:  
 
2.2.6.1. Determination of particle size, size distribution and Zeta potential: 
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NP dispersion was diluted with HEPES buffer pH 8 either 1 mM or 5 mM for particle 
size and zeta potential measurements respectively. Samples were diluted to give a count 
rate of 50 to 300 Kcps and measurements were performed at 25 °C ± 0.1 using Malvern 
Zeta sizer Nano ZS (Malvern Instruments Ltd, Malvern, UK).   
 
2.2.6.2. Determination of Drug Loading:  
RV drug loading had been determined by following the protocol previously reported 
(50) but with some modifications. A known weight of freeze dried NP was dissolved in an 
organic solvent [acetone: methanol (1:1), pH 6.5]. The phenylboronic acid cartridges 
(PBA cartridges) were pre-conditioned with phosphoric acid in methanol (1ml, 0.5% 
v/v) followed by ammonium phosphate buffer (1 ml x 3, 250 mM, pH ≥ 11.5). After 
sample (1ml) loading into the pre-conditioned cartridges, the cartridges were eluted with 
ammonium phosphate buffer (1ml x 3, 250 mM, pH ≥ 11.5), methanol (2ml) and then 
RV was eluted by addition of formic acid in methanol (1ml x 2, 2.5% v/v). The sample 
was prepared for HPLC analysis by evaporating the formic acid in methanol using a 
Juan vacuum centrifuge at 60 ̊C followed by dissolving the dried extracted RV in 
purified water (250 µl) and addition of uridine (U) solution (5 µl, 1 mg/ ml, purified 
water) as an internal standard. The sample was analysed by injection into an HPLC 
column set consisting of an Atlantis dc18 guard column (4.6 mm X 20 mm, 3 μm) 
connected to an Atlantis dc18 column (150 mm X 4.6 mm, 3 μm). Ammonium 
phosphate buffer (10 mM, pH 3.3) was used as a mobile phase at a flow rate of 1ml/min, 
temperature 40 ̊C and UV detection at 207nm. The total amount of RV entrapped was 
calculated from the calibration curve of different known RV concentrations (0.1 to 50 
µg/ml) prepared in purified water in presence of U (20 µl, 1 mg/ml, purified water) as 
an internal standard. Drug loading was calculated as follows, 
Drug loading Percentage =        
𝑨𝒎𝒐𝒖𝒏𝒕 𝑫𝒓𝒖𝒈 𝑬𝒏𝒕𝒓𝒂𝒑𝒑𝒆𝒅 (𝒎𝒈)
𝑾𝒆𝒊𝒈𝒉𝒕 𝒐𝒇 𝑵𝑷(𝒎𝒈)
∗ 100 
To identify the efficiency of RV extraction, equal concentration of RV/ PBA (20, 50 
and 100 µg/ml) in the presence of PGA (10 mg) in a mixture of acetone: methanol (1:1) 
pH 6.5 was extracted with the pre-conditioned phenylboronic acid cartridges as 
previously described and the amount of the extracted RV samples was reconstituted in 
purified water (1ml) and U (20 µl, 1mg/ml, purified water) was added followed by 
sample injection into HPLC. The efficiency of the extraction method was determined 
via calculation of the recovery percentage as follows; 
 
Recovery Percentage = 
𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 𝑜𝑓 (𝑅𝑉/𝑈)𝑆𝑎𝑚𝑝𝑙𝑒
𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 𝑜𝑓(𝑅𝑉/𝑈)𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒
∗ 100 
 
Peak area of (RV/U) sample; was calculated for the known RV concentrations that had 
been extracted from the previous RV samples (RV/PBA in presence of PGA) after being 
treated with pre-conditioned PBA columns followed by HPLC measurement. Peak area 
of (RV/U) reference; is calculated for samples of similar RV concentrations (20, 50, 
100 µg/ml, purified water) in presence of U (20 µl, 1mg/ml, purified water) that had 
been injected into HPLC directly without any pre-treatment or extraction with PBA 
columns.  
 
2.2.7. Validation of ribavirin HPLC analysis 
HPLC analysis of RV was validated by determining linearity, inter and intra-day 
variation. RV linearity was determined by using RV concentrations ranging from 0.1 to 
8 
 
50 µg/ml prepared in the purified water. The accuracy and precision of intra- day and 
inter-day variation were determined using RV concentrations, of 12.5, 25 and 50 µg/ml. 
Analysis of these concentrations was done three times in the same day at different times 
(Intra-day variation) and on different days (Inter-day variation). Again uridine (20 µl, 1 
mg/ml, purified water) was used as an internal standard. The accuracy and precision 
were calculated as follows, 
                                            Accuracy = [(M-N)/N] * 100  
M is the mean value of RV concentration measurements while N is the theoretical 
concentration. 
                                     Precision (% RSD) = [SD/Average] * 100 
RSD is the relative standard deviation, SD is the standard deviation of measurements 
and Average is the mean value of RV concentration measurements. 
2.2.8. Investigating the stability of RV-boronic ester linkage 
 
2.2.8.1. In organic phase 
RV-PBA or RV-BPBA (10 mg) was dissolved in dry acetone or dry THF respectively 
(3 ml) and left overnight for complete evaporation of organic solvent. The dried residue 
was dissolved in DMSO- d6 (1 ml) and characterised by 
1H-NMR. 
 
2.2.8.2. In aqueous phase 
RV-PBA/RV-BPBA (10 mg) was added to ammonium phosphate buffers (5 ml, 250 
mM, pH 6.5, 7.5, 8, 8.5) or calcium hydroxide solution (5 ml, 0.3 mM) and left to stir 
for 20h. For RV-PBA, 2 ml of these solutions were freeze dried to remove water. The 
freeze-dried residue was dissolved in DMSO- d6 (1 ml) and characterised by 
1H-NMR. 
For RV-BPBA, 1 ml of these solutions was centrifuged and supernatant (0.7 ml) was 
taken and pH was adjusted into 8.5 using ammonium phosphate buffer (250 mM, pH 
8.5). Then, RV was extracted by the pre-conditioned phenylboronic acid cartridges 
followed by HPLC analysis as described. Ribavirin degradation percentage was 
calculated by the following equation;  
 
𝑅𝑖𝑏𝑎𝑣𝑖𝑟𝑖𝑛 𝐷𝑒𝑔𝑟𝑎𝑑𝑎𝑡𝑖𝑜𝑛% =
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑟𝑖𝑏𝑎𝑣𝑖𝑟𝑖𝑛 𝑑𝑒𝑔𝑟𝑎𝑑𝑒𝑑 (𝑚𝑔)
𝐼𝑛𝑡𝑖𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑟𝑖𝑏𝑎𝑣𝑖𝑟𝑖𝑛 (𝑚𝑔)
∗ 100 
 
Amount of RV degraded represents the amount of RV detected in the supernatant of 
RV-BPBA samples, Initial amount of RV was determined after dissolving RV-BPBA 
(10 mg) in acetone: methanol (1:1, pH 6.5) followed by extraction as described in 
section 2.2.6.2. 
 
2.3. Statistical analysis: 
All statistical analysis was done using TWO WAY ANOVA followed by Post-hoc test 
(Tukey test). Statistical analysis was done by IBM SPSS version 21 at confidence level 
(95%). 
 
3. Results and Discussion: 
3.1. Synthesis and characterization of PGA and its acylated derivatives: A variety 
of polymers are used to prepare nanoparticles for drug delivery systems, and we believe 
that PGA has number of advantages over other available polymers.  PGA is readily 
biodegradable with biologically compatible degradation products; adipic acid and 
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glycerol that are recognized safe compounds as approved by FDA (51) and is unique 
among biodegradable polymers in being easily chemically modified through the 
pendant hydroxy group allocated along the polymer backbone to give a range of 
polymers with different physicochemical properties (48); (52); (53).  The green 
synthesis (enzymatic synthesis) of PGA avoid the harsh conditions (metal catalysts, 
high temperature required for synthesis around 120ᵒC as well as lack of stero-selectivity) 
commonly required to prepare other polyester polymers (52). In this work PGA was 
synthesised by polycondensation of divinyladipate and glycerol in THF at 50 °C for 24 
h catalysed by Lipase Enzyme, Novozyme 435 as previously reported (48) and 
described in Figure 1. PGA synthesis was demonstrated by 1H-NMR through 
disappearance of DVA vinyl proton peaks at δ 4.5 to 5 ppm and at δ 7.5 ppm in addition 
to appearance of broad polymer signals – e.g. methylene groups peaks of the adipate 
repeating units at δ 1.6 and 2.37 ppm (Figure S1, Supplementary Information). The 
resulting PGA possessed mostly linear macromolecular architecture, with largely 
predominant (85%) 1,3-diesterified glycerol repeating units. 1,2-diester units (7.5% 
mol/mol) were also observed by 1H NMR along with 1,2,3-tri-ester branching residues 
(7.5%) (Figure S2, Supplementary Information) resulting in an overalls side branching 
that does not exceed 15%. The latter had been performed by comparing the integration 
of methine group at δ 5.1 and 5.3 ppm respectively to the peak integration of methylene 
group either at δ 1.65 or 2.37 ppm as previously reported (54). However, this might be 
slightly underestimated side branching figure due to incomplete removal of THF. SEC 
analysis using THF as the mobile phase gave an estimated Mnn,SEC = 11.6 KDa and 
molecular weight dispersity Ð of 1.4 and molecular weight (Mw) = 16 KDa. Subsequent 
partial esterification of the PGA residual hydroxyl functionalities with octanoic (C8) or 
octadecanoic (C18) acid chlorides was carried out to obtain the acylated 20%-C8PGA, 
40%-C8PGA, and 20%-C18PGA polymer derivatives (Figure 1). Acylation reaction was 
demonstrated by appearance of methyl group at δ 0.9 and methylene group at δ 1.3 ppm 
(Figure 2). The degree of acylation was determined by 1H.NMR spectroscopy (Figures 
S3:S5, Supplementary Information). The acylation of PGA polymer is resulting in an 
increase of the 1,2,3-tri-ester branching residues and therefore, the integration of 
methine CH group (C2) at δ 5.3 ppm will be increased. Therefore, the relative increase 
of methine group integration was used to calculate the acylation reaction efficiency as 
follows; 
𝑻𝒉𝒆 𝒂𝒄𝒚𝒍𝒂𝒕𝒊𝒐𝒏 𝑹𝒆𝒂𝒄𝒕𝒊𝒐𝒏 𝑬𝒇𝒇𝒊𝒄𝒊𝒆𝒏𝒄𝒚 = 
 
 
[(𝑷𝒆𝒂𝒌 𝑪𝟐 𝒊𝒏𝒕𝒆𝒈𝒓𝒂𝒕𝒊𝒐𝒏 (𝒂𝒄𝒚𝒍𝒂𝒕𝒆𝒅 𝒑𝒐𝒍𝒚𝒎𝒆𝒓) − 𝑷𝒆𝒂𝒌 𝑪𝟐 𝒊𝒏𝒕𝒆𝒈𝒓𝒂𝒕𝒊𝒐𝒏 (𝑷𝑮𝑨)]
[𝑷𝒆𝒂𝒌 𝑪𝟐 𝒊𝒏𝒕𝒆𝒈𝒓𝒂𝒕𝒊𝒐𝒏 (𝒂𝒄𝒚𝒍𝒂𝒕𝒆𝒅 𝑷𝑮𝑨)]
∗ 100  
The acylation reaction was more efficient for octanoic (C8) acid chloride than the 
octadecanoic (C18) acid chlorides resulting in acylation percentage of 15%, 33.6% and 
11% for 20%C8PGA, 40%C8PGA and 20%C18PGA respectively. The acylation reaction 
of PGA was associated with an increase in the molecular weight (Mw) of polymers, as 
observed by SEC and it was 161000, 91000, and 105,000 Da for 20%C8PGA, 
40%C8PGA and 20%C18 PGA respectively. However, it reflects the size of the polymer 
rather than an accurate value of the polymer molecular weight. This is mainly due to 
calibration of SEC with polystyrene, a linear polymer (without pendant groups) and 
therefore the results obtained for the acylated polymers (20%C8PGA, 40%C8PGA, etc) 
could not be directly correlated to their molecular weight and therefore are not 
considered as a relevant molecular weight. However, the values recorded for acylated 
polymers are higher than that recorded for PGA (linear polymer without pendant 
groups). This could be indicative for the success of acylation reaction of polymer. 
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3.2. Synthesis and characterisation of RV-PBA and RV-BPBA: 
Ribavirin boronic derivatives were synthesized (Figure 3) as previously reported (49) 
to increase the hydrophobicity of RV and hence its ability to be incorporated within 
hydrophobic polymeric carriers. Chemical modification was carried out by conjugation 
of hydrophobic moieties to RV, through formation of a biodegradable boronic ester 
linkage. The synthesis reaction was carried out in a 250 ml-RBF using an equimolar 
amount of RV and phenyl boronic acid (PBA) or 4-butoxy-3,5-dimethylphenylboronic 
acid (BPBA), and following extraction and purification, afforded the desired ribavirin 
boronic esters in 77% and 69% yields for RV-PBA and RV-BPBA, respectively. 
Virtually complete conversion of ribavirin into RV-PBA and RV-BPBA was confirmed 
by 1H NMR analysis (Figure 4) which showed the appearance of HCOB peaks 4 and 3 
at δ 5.4 and 5.65 ppm respectively, along with that of phenyl proton peaks at δ 6.5 - 7.9 
ppm.  
 
3.3. Drug Extraction from nanoparticles and validation of HPLC analysis 
For development and validation of an extraction method for drug quantitation from 
nanoparticles loaded with RV-boronic acid derivatives, samples simulating the RV-
boronic acid derivatives loaded into nanoparticles were prepared. Each sample 
contained a known weight of PGA polymer and appropriate amounts of RV and PBA 
at equal concentration. Drug was extracted from these samples to determine the 
efficiency of the extraction methodology.  
The extraction method was based on the protocol that was reported by Arianna with 
some modifications (55). The principle of the extraction method depends on the lability 
of the boronic ester linkage at acidic pH. The boronic ester linkage is formed and has a 
high stability at alkaline pH while it degrades at acidic pH. To extract RV from 
polymeric NP, an acidic organic solvent (acetone: methanol (1:1), pH ≤ 6.5) was used 
to dissolve the polymeric matrix and cleave the boronic ester linkage releasing RV. RV 
was then extracted with pre-conditioned PBA cartridges. Pre-conditioned PBA 
cartridges should offer an alkaline pH-dependant specific and selective interaction 
between Cis-diol group of ribose moiety of RV and boronate groups of PBA cartridges 
to form boronic ester link and therefore RV becomes selectively attached to PBA 
cartridges. To elute RV for HPLC analysis, an acidic solvent (formic acid in methanol, 
2.5%) was used to break down the boronic ester linkage. HPLC analysis showed that 
RV and U peak retention times appeared at 5.2 and 8.8 minutes respectively (Figure S6, 
Supplementary Information).  The extraction efficiency was expressed as the recovery 
percentage ± (%RSD), and it was found to be 91% ± 5.2 (RSD%), 97 ± 2 and 100% ± 
3.6(RSD%) for 20, 50 and 100 µg/ml respectively. Validation of HPLC analysis method 
showed that a calibration curve for RV concentrations ranging from 0.1 to 50 µg/ml was 
linear with a correlation coefficient (R2) equal to 0.999. Limit of Detection (LOD) and 
Limit of Quantification (LOQ) were equal to 0.616 and 1.86 µg/ml respectively. Three 
different concentrations of RV (12.5, 25, 50 µg/ml) were used to evaluate intra-day and 
inter-day variations using U (20 µl, 1 mg/ml, purified water) as an internal standard. 
The accuracy of intra-day and inter-day variation ranged from 0.14 to 0.78 and from 1.8 
to 3 respectively. The precision (Practical %RSD) ranged from 0.04% to 0.45% for 
intra-day variation and from 1.06% to 2.4% for inter-day variation indicating a high 
degree of repeatability. In accordance with AOAC guidelines (56; 57), the following 
equations were used to calculate the theoretical RSD% for intra-day and inter-day 
variation respectively, % RSD of repeatability = C -0.15 and % RSD of repeatability = 2 
C -0.15 where C is the analyte concentration expressed as mass fraction. The accepted 
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practical %RSD for a valid method should range between ½ and 2 times of the 
theoretical calculated values. Those values that were obtained in the present study 
indicating the validity of the method used for RV analysis. 
 
3.4. Characterisation of nanoparticles and drug loading 
3.4.1. Particle size and Zeta potential measurements:  
The particle size measurements of RV, RV-PBA, and RV-BPBA nanoparticles prepared 
with PGA, 20%-C8PGA and 40%-C8PGA, 20%-C18PGA were performed in HEPES 
buffer (1mM, pH 8) to prevent breakdown of encapsulated boronic acid derivatives. 
Nanoparticle samples were prepared in triplicate and particle size for all nanoparticles 
are presented as the average value of particle size diameter (nm). The particle size of 
RV/RV-PBA/ RV-BPBA NP prepared with PGA polymer was 85, 99, and 88 
respectively and their sizes were non-significantly (P > 0.05) different from the particle 
size of the BLANK PGA nanoparticles 104, Table 1. 
Use of acylated polymers to prepare RV-PBA/RV-BPBA NP in absence of Tween 80 
produces significantly (P < 0.05) larger particle size (about 129 to 190 nm) than NP 
prepared with PGA polymer. NP prepared with 20% and 40% C8PGA polymers had a 
particle size range, 140-160nm although the particles with a significant drug loading 
were slightly larger, about 170nm. NP prepared with 20%-C18 PGA polymer have a 
similar size to NP prepared with C8PGA polymers except RV-BPBA C18PGA NP (drug 
conc,1mg/ml) had a larger particle size, 190nm. Another set of C18PGA NP was 
prepared in presence of Tween 80 and it resulted in a significant (P < 0.05) decrease of 
particle size for RV-PBA NP to be around 100nm while the size of RV-BPBA NP was 
either the same (190nm) or larger (269nm).  
 
The poly dispersity index (PDI) for nanoparticles prepared with PGA, 20%-C8PGA and 
40%-C8PGA was small indicating high degree of homogeneity and a low tendency of 
particle aggregation. In contrast, the PDI of NP prepared with 20%-C18PGA was much 
higher than those prepared with C8PGA polymers and this is indicative of a high 
tendency to aggregate formation. Consequently, 0.05% Tween 80 was added during the 
nanoprecipitation to control the aggregate formation. However, Tween 80 had a little 
effect on the polydispersity of RV-PBA NP, while for the BPBA derivative, the 
polydispersity remained the same and particle size was the same or larger and this 
indicated the little effect of tween to control particle aggregation.   
 
The larger particle size obtained for acylated polymers compared to PGA polymer may 
be due to the size of the acyl groups that might increase the size of the particle core or 
alternatively by an increase in the aggregation number due to the increase 
hydrophobicity of the polymer (48). Bilati and his colleagues (58) reported that organic 
solvent with a lower dielectric constant resulted in nanoparticles with a larger particle 
size. Guhagarkar and his colleagues (59) reported a decrease of the particle size when 
Acetone: THF (1:1) were used as a solvent compared to the particle size obtained using 
THF alone as a solvent and it was rationalized to the rapid diffusion of the more polar 
solvent resulting in rapid precipitation of the polymer that favours formation of small 
particles. Therefore, solvent may have an effect on the particle size produced from 
different polymers.  
Surfactant addition may enhance NP formation due to (1) reduction of the surface 
tension of the polymer during particle formation when the latter came into contact with 
water and so promote the polymer assembly into NP (2) The possibility of interaction 
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of the acyl chain of surfactant with the polymer may enhance the packing of polymer 
molecules and hence, a small particle size could be obtained (48). Tween 80 is a non-
ionic surfactant that could stabilize NP through steric effects. As a simple nanoparticle 
surface interaction, this might reduce the tendency of nanoparticles to aggregate which 
may result in smaller nanoparticles where it is expected that Tween will form a 
monolayer coat around nanoparticles. It had been reported (60) that 10 µg of Tween 
80/Unit mg of NP is required to form a monolayer coat around PLGA NP (no drug was 
included), have a size 150nm at Tween80 concentration 0.05%. It had been found that 
there are no significance changes of the amount of Tween80 adsorbed onto the surface 
of NP or NP size upon increasing the concentration of Tween80 and this is indicative 
of surface saturation. This is matched with the previous reported data (61) where 
adsorption of Tween 80 onto the surface octadecyltriethoxysilane resulting in formation 
of a monolayer of 2nm thickness. Nanoparticles prepared with 20%-C18PGA polymer 
have a size ranged from 129 to 190nm and therefore, it was expected that Tween 80 
(0.05%) should be enough to stabilize the system but there may be a range of much 
more complex interactions as the nanoparticles form that could involve the drug and 
surfactant as well as the polymer and surfactant. The surfactant could interact in ways 
which affect the aggregation number of polymer and drug molecules resulting in either 
smaller or larger particles depending on whether a smaller or larger number of 
interactions were favoured.  This may be influenced by the hydrophobicity or other 
properties of the drug present. Diclophenac chitosan nanoparticles (62) prepared in 
presence of different concentration of Tween 80; 0%, 0.01%,0.02% and 0.03% have a 
particle size 108nm, 110nm, 128nm and 148nm respectively. Upon tracking the 
precipitation rate of formulations prepared at 0.03% and 0.02% of Tween 80, it was 
found that nanoparticles precipitated out from the solution after 24h and 48h 
respectively. It was expected that an increase of surfactant concentration should keep 
the stability of the formulation, but it wasn’t the case. In the current study Tween 80 
had imparted an initial decrease of the particle size of RV-PBA 20%-C18PGA NP while 
no change or an increase of the particle size for RV-BPBA C18PGA NP but all 
nanoparticles prepared with 20%-C18PGA polymer had a high PDI value ≥ 0.3 and this 
is indicative of the instability of the system with tendency of particle aggregation. 
Another study that had been performed by Navneet and his colleagues where Tween 80 
was used as a co-surfactant at concentration 0.05%, had resulted in decreasing the 
particle size of paclitaxel nanoparticles prepared with PLGA from 438 to 389nm but it 
was accompanied by an increase of PDI from 0.19 to 0.39 and this is indicative of 
system instability with a high tendency of particle aggregation (63). Tween 80 was 
added in the present work in a small quantity to minimize possible downstream 
problems, as it was reported that polysorbate addition could alter the in vivo particle 
bio-distribution at high surfactant concentration (64). 
 
The zeta potential data of all NP were presented as Zeta potential (mv) ± SD where all 
sample measurements were performed in HEPES buffer (5mM, pH 8). All NP were 
stable as indicated by the high negative zeta potential value, around -50 mV, Table 1. 
The negative surface charge is attributed to the free COOH group in each polymer chain 
that could result in charge stabilisation and therefore a lower possibility of aggregate 
formation. The closeness of zeta potential value for NP prepared with different 
polymers might be due to the choice of HEPES buffer (5mM, pH8) for the zeta potential 
measurements. The alkaline pH is essential for the stability of the boronic ester linkage 
of pro-drugs but it also ionizes all carboxylic group presents on the polymer chain. It 
was expected that addition of Tween 80 might reduce the negative value of zeta 
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potential due to polyethylene-oxide groups of Tween 80 (48) but this was not seen in 
the current study. This may be due to the short chain length of PEG in Tween, and the 
low concentration of Tween 80 used which may result in a low particle surface coverage 
of surfactant and consequently a flattened PEG layer which was too thin to influence 
the zeta potential.  
 
3.4.2. Drug loading 
In many drug encapsulation studies there is a relatively inefficient separation of free 
drug from encapsulated drug resulting in quite high drug loadings with rapid apparent 
drug release. We have used a gel filtration separation resulting in a very efficient 
removal of all free drug to give a more accurate measure of drug loading.  
To determine drug loading, drug was efficiently extracted from the NP using pre-
conditioned PBA cartridges as previously described in section 2.2.6.2. RV is a 
hydrophilic drug and it is expected to have a very low drug loading into polymer 
nanoparticles and therefore polymers of different physicochemical properties, PGA and 
acylated PGA were used to prepare NP of RV-boronic derivatives of different 
hydrophobicity to investigate conditions that may improve drug loading. Due to 
problems with NP aggregation during NP preparation with acylated polymers, calcium 
hydroxide solution (0.3 mM) was used as the aqueous medium instead of HEPES buffer 
(10 mM, pH 8). This aqueous phase offered the alkaline pH necessary for the stability 
of boronic ester linkage and had a minimum polymer aggregation with a good yield of 
NP formation. 
PGA NP: RV NP prepared with PGA polymer showed a very low % drug loading. 
0.001 ± 0.001. This figure is much lower than other reported results for drug loading of 
nucleosides into biodegradable polymer nanoparticles and may result from the very 
efficient separation method used in the present work. The drug loading for RV-PBA 
and RV-BPBA was 0.002 ± 0.001 and 0.001 ± 0.000  respectively, Table 1. So, the use 
of RV pro-drugs with PGA polymer did not improve drug loading. Acylated PGA 
polymers were therefore also investigated in these drug loading studies.  
Acylated PGA NP: PGA was functionalized with different acyl chain length (C8/C18) 
and different acylation percentage (20% and 40%) to produce polymers with different 
hydrophobicity and were used to prepare nanoparticles of RV boronic derivatives.  
At a pro-drug concentration of 1mg/ml, 20%-C8PGA polymer had a slight enhancement 
of RV-PBA drug loading (0.025 ± 0.020), however, other combinations of C8PGA 
polymers with RV-PBA showed no improvement of drug loading over that achieved by 
RV PGA NP. In contrast, there was a marked improvement of drug loading for 
Nanoparticles of RV-BPBA, where 40%-C8PGA and 20%-C8PGA polymers, at a pro-
drug concentration of 2 mg/ml had 700 times (0.7 ± 0.4) and 1700 times (1.7 ± 1) 
increase of drug loading respectively, Table 1. 
Using 20%-C18PGA polymer in absence of tween 80, only RV-BPBA at a prodrug 
concentration 2mg/ml (0.056 ± 0.050) showed an improvement of drug loading over 
RV PGA NP. In the presence of tween 80, a doubling of drug loading (0.134 ± 0.050) 
for RV-BPBA at the same drug concentration was recorded.  While at RV-BPBA 
concentrations; 1 mg/ml drug loading (0.100 ± 0.100) was improved by 100 times, Table 
1. Drug loading of RV boronic derivatives achieved by Nanoparticles prepared with  
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Table 1: Physicochemical characteristics and drug loading of RV, RV-PBA and RV-BPBA nanoparticles prepared with PGA, 20%-C8PGA, 
40%-C8PGA and 20%-C18PGA polymers  
Sample Name (Drug Conc, mg/ml) *P. S. dnm [SD] (PDI) *Zeta Potential ± SD *% Drug Loading ± SD 
BLANK PGA (0) 104 [13] (0.1) -56 ± 13 ------- 
RV PGA (4) 85 [11] (0.13) - 47 ± 12 0.001± 0.001 
RV-PBA PGA (2) 99 [8] (0.14) - 67.9± 13 0.002 ± 0.001 
RV-BPBA PGA (2) 88[10] (0.14) - 50 ± 15 0.001 ± 0.000 
RV-PBA 20% - C8 PGA (1) 152 [2] (0.05) - 69 ± 8 0.025 ± 0.020 
RV-PBA 20% - C8 PGA (2) 167 [8] (0.09) - 65 ± 11 0.001± 0.000 
RV-PBA 40% - C8 PGA (1) 148 [1] (0.1) - 64 ±10 0.001 ± 0.000 
RV-PBA 40% - C8 PGA (2) 138 [5] (0.07) - 63 ±10 0.001 ± 0.000 
RV-BPBA 20% - C8 PGA (1) 143 [7] (0.16) - 41± 9 0.150 ± 0.130 
RV-BPBA 20% - C8 PGA (2) 175 [5] (0.12) - 44 ± 9 1.700 ±1.000 
RV-BPBA 40% - C8 PGA (1) 138 [9] (0.25) - 52 ±10 0.050 ± 0.030 
RV-BPBA 40% - C8 PGA (2) 170 [14] (0.13) - 51 ±10 0.700 ± 0.400 
RV-PBA 20%- C18PGA (1) 156 [3] (0.5) - 33 ± 13 0.003 ± 0.001 
RV-PBA 20%- C18PGA (2) 136 [6] (0.4) - 52 ±16 0.004 ± 0.003 
RV-BPBA 20%- C18PGA (1) 190 [42] (0.4) - 59 ±12 0.004 ± 0.003 
RV-BPBA 20%- C18PGA (2) 129 [22] (0.4) - 55 ±23 0.056 ± 0.050 
RV-PBA 20%- C18PGA (1) plus Tween 80  106[17] (0.4) - 47±12 0.004 ± 0.003 
RV-PBA 20%- C18PGA (2) plus Tween 80 107 [0] (0.3) - 54 ±15 0.010 ± 0.010 
RV-BPBA 20%- C18PGA (1) plus Tween 80 193 [36] (0.4) - 54 ±15 0.100 ± 0.100 
RV-BPBA 20%- C18PGA (2) plus Tween 80 269 [110] (0.3) - 56 ±13 0.134 ± 0.050 
*Average of 3 samples – Drug Conc; Drug Concentration (mg/ml), P.S; Particle size (diameter, nm), SD; Standard Deviation, PDI; polydispersity index, 
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20%-C18PGA polymer showed a slight improvement over that achieved by PGA 
polymer but still significantly (P < 0.05) very low compared to drug loading achieved  
by C8PGA polymers. This is probably due to the high tendency of 20%-C18PGA 
polymer to form aggregates, as a result of their long acyl chain length and very high 
hydrophobicity. Overall, the presence of tween was not very successful in controlling 
aggregation but did lead to some increase in drug loading.  RV-boronic derivatives have 
more hydrophobic properties; RV-BPBA> RV-PBA> RV, Table 2. Although, it was 
believed that both RV-boronic derivatives should be accompanied with an improvement 
of drug loading, this was only found with RV-BPBA. Also, it was expected that 
increasing hydrophobicity of polymers (increased acyl substitution, increased acyl 
chain length) would be associated with an increase of drug loading. However, the 
highest drug loading was achieved with 20%-C8PGA polymer which has intermediate 
hydrophobicity. This led us to two questions, (1) why RV-PBA did not achieve any 
marked improvement of the drug loading? - and (2) what is the relationship between 
hydrophobicity and drug loading? 
 
The first question led us to a further investigation about the stability of both RV-boronic 
derivatives under the conditions of nanoparticle preparation. The stability of RV-PBA 
and RV-BPBA was investigated in both organic and aqueous phases.1H.NMR analysis 
was used to estimate the degradation percentage of boronic ester linkage in organic 
phase and RV-PBA stability in aqueous phase while HPLC analysis was used to track 
degradation of RV-BPBA in the aqueous phase. RV-BPBA and RV-PBA degradation 
percentage in organic phase was calculated from 1H.NMR spectra and it was found to 
be 39% (Figure 5) and 45% (Figure 6) respectively. HPLC analysis showed that RV-
BPBA degradation percentage in ammonium phosphate buffers ranged from 27.6% to 
33% and the least degradation was in calcium hydroxide solution, 23%. In contrast, RV-
PBA was almost completely degraded in all aqueous media (Figure 7). Therefore, the 
higher stability of RV-BPBA under the conditions of NP preparation could account for 
the higher drug loading achieved for RV–BPBA and the lack of drug incorporation by 
RV-PBA. The sensitivity of these drugs to degradation may also have been responsible 
for the variability seen in some of the drug loading results for RV-BPBA. The remaining 
amount of stable pro-drugs in the solution under the condition of nanoparticle 
preparation should be available to be incorporated into the polymer nanoparticles. 
Therefore, the drug loading percentage determined for each pro-drug/polymer 
formulation could reflect the stability of the pro-drug loaded into nanoparticle. The full 
degradation of RV-PBA prodrug means that RV rather than RV-PBA will be available 
to be incorporated into the polymer nanoparticle and therefore, no marked improvement 
of drug loading percentage had been recorded, see Table 1. For RV-BPBA, 40% of 
initial intact pro-drug is still stable under the condition of nanoparticle preparation and 
is available for incorporation into polymer nanoparticles. Therefore, it was associated 
with an improvement of drug loading percentage. However, the improvement of drug 
loading differs for each polymer used for nanoparticles preparation.  
RV-BPBA achieved the highest drug loading in the following order for these polymers 
20%-C8PGA > 40%-C8PGA > 20%-C18PGA, this indicate that drug loading is not 
directly related to the hydrophobicity for this particular drug, so is there some other 
relationship between hydrophobicity and drug loading? 
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The hydrophobicity of a compound is expressed by its Clog P value. The values 
presented in Table 2 is Clog p values for a single basic unit of PGA polymer (co-
monomer of glycerol and divinyl-adipate), its acylated derivatives, the methyl ester of 
C8 and C18 moieties, RV and RV-boronic derivatives. These Clog P values have been 
calculated using Chemdraw software. Moving from a negative to a positive value of 
Clog P is indicative of a change from a hydrophilic to a hydrophobic compound with 
greater values indicating an increase of the hydrophobic properties of the compound. 
 
Therefore, polymers could be arranged according to an increase of the hydrophobic 
properties as follows PGA< C8PGA<C12PGA< C18PGA. This aligned with the increase 
of the hydrophobicity of the methyl ester of the acylated chains; C8 methyl ester < C12 
methylester < C18 methylester.  It is worth noting that Clog P value presented in the 
table represented 100% acylation of the single basic unit of PGA while in the current 
study, polymer acylation had been performed using two different percentage; 20% and 
40% using the acyl chloride of C8 and C18. Although it was not possible to get sensible 
calculations from Chemdraw for these more complex mixtures of monomers, the more 
acylation percentage, the higher hydrophobic properties of the polymer and 
consequently a higher Clog P value is expected. Values for C12 PGA and C12 
methylester was calculated and presented to show the direct proportionality between the 
increase of acyl chain length and the increase of Clog P value. The hydrophobicity of 
compounds was a concern because it is believed that the hydrophobicity might have a 
role in drug loading and this could be through hydrophobic attraction forces (e.g. van 
der waals attraction forces) between the aromatic rings of the boronic compounds 
derivatives and the acyl chains of acylated polymers in the aqueous phase and therefore 
an improvement of drug loading. Furthermore, the hydrophobicity of the 
compounds/polymers might have an effect on the precipitation rate of 
compounds/polymers in the aqueous phase. We believe that the co-precipitation of 
compound and polymer might be accompanied by enhancement of drug loading into 
polymer nanoparticles.  
 
Bodmeier and McGinity (65) reported that the successful entrapment of drug within the 
nanoparticles depends on several factors; (a) low solubility of drug in the aqueous 
phase; (b) a fast rate of precipitation/solidification of the polymer in the organic phase 
which in turn depends on high aqueous phase solubility and high vapor pressure of 
solvent, and low viscosity of the internal phase; and (c) high solid-state solubility of 
Table2: Clog P value for Polymers, acyl methyl esters, RV and RV boronic 
derivatives 
 
Polymer *Clog P 
Acyl methyl ester *Clog P Drug/Pro-drug 
*Clog 
P PGA -0.38 
C8PGA 4.17 C8 methyl ester 3.36 RV -2.85 
C12PGA 6.29 C12 Methyl ester 5.47 RV-BPA -1.14 
C18PGA 9.46 C18 Methyl ester 9.62 RV-BPBA 1.36 
*Clog P value, a parameter measures the hydrophobicity of the compound. Clog P values were 
calculated using Chem-draw software. Negative charge indicates increasing hydrophilicity. Clog P 
value for PGA represents its basic unit and this means that the Clog P value for the polymer backbone 
should be higher depending on the polymer molecular weight.  
17 
 
drug in the polymer and this is indicative of high compatibility and miscibility between 
drug and polymer. 
 
For Nanoprecipitation method, the organic solvent should be miscible with the aqueous 
phase and have a high vapour pressure (high evaporation rate), this allows rapid 
precipitation of the polymer with a lower tendency of the drug to escape into the aqueous 
medium. RV-BPBA is a hydrophobic compound and consequently it preferentially 
partitions into the organic phase and only escape slowly into the aqueous phase. 
Therefore, rapid evaporation of organic solvent is accompanied by precipitation of the 
drug and the polymer. At this stage, another factor will play an important role in drug 
loading and it is the rate of precipitation of both polymer and drug. We believe, if they 
have a similar or close rate of precipitation, this will result in a high drug loading but if 
the rate of precipitation differs, this will be accompanied by a low drug loading. The 
hydrophobicity of the compound/polymer will likely control the rate of precipitation. 
Clog P value of C8PGA is much closer to RV-BPBA than C18PGA polymer (table 2) 
and therefore we expect (1) a high hydrophobicity of C18PGA compared to RV-BPBA, 
may result in aggregation of that component separately and so becoming unavailable 
for co-incorporation into nanoparticles (2) a more similar precipitation rate for C8PGA 
and RV-BPBA with a high opportunity for co-precipitation forming nanoparticles (3) a 
better miscibility and compatibility between RV-BPBA/C8PGA than RV-
BPBA/C18PGA. This could be mediated either through better physical interaction 
and/or possibly less phase separation of the pro-drug from the polymeric matrix (66). 
All together, these processes allow a better chance for RV-BPBA to be entrapped into 
C8PGA and consequently a higher drug loading for C8PGA than C18PGA. This could 
also explain the slightly higher drug loading achieved for RV-BPBA with 20%C8PGA 
(1.7 ± 1) versus 40%C8PGA (0.7 ± 0.4).  The Organic solvent may also influence drug 
loading, Guharkarkar et al (59) reported that Acetone: THF (1:1) resulted in a lower 
drug loading compared to THF and this was rationalized to the rapid diffusion of the 
acetone that might be associated with a high tendency of the drug to escape to the 
aqueous phase. The poor stability of these pro-drugs in aqueous solvent may help to 
accentuate any differences of hydrophobicity and may partly explain the high variability 
seen in the drug loading results. 
 
Ishihara and his colleagues (67) reported a drug loading of (1.6 ± 0.2) for ribavirin 
monophosphate loaded into polylactic acid (PLA) together with an arabanogalactan-
polylysine copolymer in the presence of iron. The loading of RMP depended on the 
ionic bridge between the phosphate group of RMP and the carboxy group of PLA with 
the iron (III) ion to enhance drug loading of ribavirin. It is noteworthy that we have 
achieved a similar drug loading, through consideration of hydrophobic interactions 
between drug and polymer. 
 
4.Conclusion:  
Nucleoside analogues are the leading therapeutic agents for treatment of many critical 
diseases such as Cancer, AIDS, hepatitis B and C. Their therapeutic benefit is 
compromised due to side effects accompanying their clinical administration. 
Nanoparticles as an advanced delivery system could encapsulate and target nucleoside 
analogues to the diseased organ and minimize or prevent their side effects. However, 
low drug loading of the hydrophilic nucleoside analogues into nanoparticles remains an 
obstacle. This article reports a new idea that could selectively convert a hydrophilic 
nucleoside with a vicinal diol into a more hydrophobic biodegradable pro-drug through 
18 
 
formation of the boronic ester linkage to improve the drug loading. RV drug loading 
was improved enormously (average 1700 times) by developing the more hydrophobic 
boronic ester pro-drugs (RV –BPBA) and this massive increase of drug loading 
appeared to depend on the polymer and pro-drug having similar hydrophobic properties. 
These studies showed however, that sufficient encapsulation was also dependent on the 
stability of the pro-drug, so further improvements may be seen by the selection of 
boronic acid reagents which result in more stable boronic acid esters. This may also 
require a further optimisation of polymer through acyl or other modifications e.g. 
boronic compounds to obtain the best combination of polymer and drug properties for 
this novel route of nanoparticle development. 
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Figure 1: Synthesis of poly(glycerol-adipate), 20% and 40%- C8 and C18 poly(glycerol-adipate) 
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Figure 2: 1H-NMR spectra of (A) PGA, (B) 20%-C8PGA, (C) 40%-C8PGA; (D) 20%-C18PGA; acylation of PGA backbone was 
demonstrated by appearance of methyl (g) and methylene peaks (f) at δ 0.9 or 1.3 ppm.
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Figure 3: Synthesis of RV-PBA and RV-BPBA. 
 
 
 
Figure 4: 1H-NMR spectra of (A) RV-BPBA/ (B) RV-PBA/ (C) RV/ (D) PBA/ (E) BPBA; spectrum demonstrated 
the formation of RV-BPBA and RV-PBA with around 100% purity as seen from peaks 3’ and 4’ at δ 5.65 and 5.4 
ppm respectively.
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Figure 5: Stability of RV-BPBA in acetone; The degradation of  boronic ester was around 39% and it was 
calculated via dividing peak area of 2 by the summation of peak era of 2’and 2 as follows; the Boronic ester link 
degradation % = (
𝑰𝒏𝒕𝒆𝒈𝒓𝒂𝒕𝒊𝒐𝒏 𝒐𝒇 𝒑𝒆𝒂𝒌 𝟐
𝒔𝒖𝒎 (𝒊𝒏𝒕𝒆𝒈𝒓𝒂𝒕𝒊𝒐𝒏 𝒐𝒇 𝒑𝒆𝒂𝒌 𝟐+𝒊𝒏𝒕𝒆𝒈𝒓𝒂𝒊𝒐𝒏 𝒐𝒇 𝒑𝒆𝒂𝒌𝟐′
) ∗ 100. 
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Figure 6: Stability of RV-PBA in acetone; The degradation of  boronic ester was around 45% and it was 
calculated via dividing peak area of (2) by the summation of peak era of 2’ and 2 as follows; the Boronic ester 
link degradation % = [
𝑰𝒏𝒕𝒆𝒈𝒓𝒂𝒊𝒐𝒏 𝒐𝒇 𝒑𝒆𝒂𝒌 𝟐
𝑺𝒖𝒎 (𝒊𝒏𝒕𝒆𝒈𝒓𝒂𝒊𝒐𝒏 𝒐𝒇 𝒑𝒆𝒂𝒌 𝟐+ 𝒊𝒏𝒕𝒆𝒈𝒓𝒂𝒊𝒐𝒏 𝒐𝒇 𝒑𝒆𝒂𝒌 𝟐)′
] ∗ 100. 
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Figure 7: 
1
H-NMR spectra revealing the stability of boronic ester link of RV-PBA in aqueous media: 
1
H-
NMR spectra of RV-PBA degraded in calcium hydroxide solution 0.3 mM (A) and ammonium phosphate buffer, 
250 mM, pH 8.5 (B), pH 8 (C), pH7.5 (D) and pH6.5 (E) in combination of 
1
H-NMR spectra of pure ribavirin (F), 
intact RV-PBA (G) and PBA (H), showed that RV-PBA is almost completely degraded in aqueous media and this 
explains why it was not associated with any improvement of drug loading into NP prepared by different polymers. 
 
